SE1267869T5 - - Google Patents

Info

Publication number: SE1267869T5
Authority: SE; Sweden
Prior art keywords: dependence; antagonist; tolerance; nervosa; mglur5
Prior art date: 2000-03-09

Application number

SE01910051T

Other languages

Other versions

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-09

Filing date

2001-03-09

Publication date

2004-09-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9887294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE1267869(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-03-09 Application filed filed Critical

2004-08-31 Publication of SE1267869T3 publication Critical patent/SE1267869T3/xx

2004-09-07 Publication of SE1267869T5 publication Critical patent/SE1267869T5/xx

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Addiction (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Immunology (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Pathology (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Orthopedics, Nursing, And Contraception (AREA)
Medicinal Preparation (AREA)
Fertilizers (AREA)

SE01910051T 2000-03-09 2001-03-09 SE1267869T5 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0005700.0A GB0005700D0 (en)	2000-03-09	2000-03-09	Therapy

Publications (2)

Publication Number	Publication Date
SE1267869T3 SE1267869T3 (fr)	2004-08-31
SE1267869T5 true SE1267869T5 (fr)	2004-09-07

Family

ID=9887294

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE01910051T SE1267869T5 (fr)	2000-03-09	2001-03-09

Country Status (16)

Country	Link
US (1)	US20030195139A1 (fr)
EP (1)	EP1267869B1 (fr)
JP (1)	JP2003525902A (fr)
CN (1)	CN1427720A (fr)
AT (1)	ATE267013T1 (fr)
AU (1)	AU783869B2 (fr)
CA (1)	CA2402341A1 (fr)
DE (1)	DE60103384T2 (fr)
DK (1)	DK1267869T3 (fr)
ES (1)	ES2220727T3 (fr)
GB (1)	GB0005700D0 (fr)
NZ (1)	NZ521228A (fr)
PT (1)	PT1267869E (fr)
SE (1)	SE1267869T5 (fr)
TR (1)	TR200401862T4 (fr)
WO (1)	WO2001066113A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1539149B1 (fr) *	2002-09-10	2012-01-04	Novartis AG	Combinaisons d'antagonistes des recepteurs metabotropiques du glutamate et leur utilisation pour traiter les troubles de la dependance
EP2982372B1 (fr) *	2005-04-05	2020-08-05	Yale University	Agents de modulation du glutamate pour le traitement de troubles mentaux
WO2006121919A2 (fr) *	2005-05-05	2006-11-16	Massachusetts Institute Of Technology	Procedes de traitement de trouble obsessionnel compulsif
CA2620333A1 (fr)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenese par modulation du recepteur muscarinique
EP2258357A3 (fr)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenèse avec inhibiteur de l'acetylcholinestérase
WO2007035823A2 (fr) *	2005-09-20	2007-03-29	Molecular Neuroimaging, Llc	Antagonistes partiels de mglur5 et leurs méthodes d'utilisation
WO2007047978A2 (fr)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation de la neurogenese par inhibition de la pde
EP1942879A1 (fr)	2005-10-31	2008-07-16	Braincells, Inc.	Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
DE102005062985A1 (de) *	2005-12-28	2007-07-05	Grünenthal GmbH	Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
WO2007134077A2 (fr)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenèse induite par le récepteur 5ht
JP2009536669A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	アンジオテンシン調節による神経新生
KR20090064418A (ko)	2006-09-08	2009-06-18	브레인셀즈 인코퍼레이션	4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
ES2610508T3 (es)	2006-11-22	2017-04-27	Clinical Research Associates, Llc	Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
WO2010099217A1 (fr)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
EP2544688B1 (fr)	2010-03-02	2016-09-07	President and Fellows of Harvard College	Procédés et compositions pour le traitement du syndrome d'angelman
US20110294879A1 (en)	2010-05-28	2011-12-01	Xenoport, Inc.	Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en)	2010-07-15	2012-01-19	Xenoport, Inc.	Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (fr)	2010-10-21	2012-04-26	Massachusetts Institute Of Technology	Méthodes de traitement de troubles épileptiques
US20130123254A1 (en) *	2011-09-30	2013-05-16	Barbara Biemans	Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
GB201312800D0 (en)	2013-07-17	2013-08-28	Heptares Therapeutics Ltd	mGlu5 modulators
EP3661501A1 (fr)	2017-07-31	2020-06-10	Novartis AG	Utilisation de mavoglurant dans la réduction de l'utilisation d'alcool ou dans la prévention de rechute dans l'utilisation d'alcool
KR20250048143A (ko) *	2017-07-31	2025-04-07	노파르티스 아게	코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
KR102850517B1 (ko) *	2020-07-17	2025-08-25	노파르티스 아게	오피오이드 사용 감소 치료에 사용하기 위한 mglur5 길항제 마보글루란트
US20240082215A1 (en) *	2020-12-14	2024-03-14	Novartis Ag	Use of mglur5 antagonists for treating gambling disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5958459A (en) *	1991-12-24	1999-09-28	Purdue Pharma L.P.	Opioid formulations having extended controlled released
US5543698A (en) *	1994-09-27	1996-08-06	Allen-Bradley Company, Inc.	Method and apparatus used with AC motor for detecting unbalance
GB9609976D0 (en) *	1996-05-13	1996-07-17	Lilly Industries Ltd	Pharmaceutical compounds
ES2255152T3 (es) *	1997-03-14	2006-06-16	The Johns Hopkins University	Composiciones y metodo de proteinas de activacion sinaptica.
TW544448B (en) *	1997-07-11	2003-08-01	Novartis Ag	Pyridine derivatives
US6057368A (en) *	1998-08-05	2000-05-02	Brookhaven Science Associates Llc	Treatment of addiction and addiction-related behavior
BR9914215A (pt) *	1998-10-02	2001-07-03	Novartis Ag	Antagonistas de mglur5 para o tratamento da dor e da ansiedade
TW593241B (en) *	1999-04-20	2004-06-21	Hoffmann La Roche	Carbamic acid derivatives
AU4797400A (en) *	1999-05-17	2000-12-05	Eli Lilly And Company	Metabotropic glutamate receptor antagonists
US6666209B2 (en) *	2001-02-20	2003-12-23	3M Innovative Properties Company	Method and system of calibrating air flow in a respirator system

2000
- 2000-03-09 GB GBGB0005700.0A patent/GB0005700D0/en not_active Ceased
2001
- 2001-03-09 AT AT01910051T patent/ATE267013T1/de not_active IP Right Cessation
- 2001-03-09 US US10/221,128 patent/US20030195139A1/en not_active Abandoned
- 2001-03-09 SE SE01910051T patent/SE1267869T5/xx unknown
- 2001-03-09 ES ES01910051T patent/ES2220727T3/es not_active Expired - Lifetime
- 2001-03-09 AU AU37634/01A patent/AU783869B2/en not_active Ceased
- 2001-03-09 CA CA002402341A patent/CA2402341A1/fr not_active Abandoned
- 2001-03-09 DE DE60103384T patent/DE60103384T2/de not_active Revoked
- 2001-03-09 WO PCT/GB2001/001058 patent/WO2001066113A1/fr not_active Ceased
- 2001-03-09 CN CN01808891A patent/CN1427720A/zh active Pending
- 2001-03-09 PT PT01910051T patent/PT1267869E/pt unknown
- 2001-03-09 DK DK01910051T patent/DK1267869T3/da active
- 2001-03-09 EP EP01910051A patent/EP1267869B1/fr not_active Revoked
- 2001-03-09 NZ NZ521228A patent/NZ521228A/en unknown
- 2001-03-09 TR TR2004/01862T patent/TR200401862T4/xx unknown
- 2001-03-09 JP JP2001564765A patent/JP2003525902A/ja active Pending

Also Published As

Publication number	Publication date
AU783869B2 (en)	2005-12-15
SE1267869T3 (fr)	2004-08-31
EP1267869B1 (fr)	2004-05-19
JP2003525902A (ja)	2003-09-02
CN1427720A (zh)	2003-07-02
EP1267869A1 (fr)	2003-01-02
DE60103384T2 (de)	2005-06-16
AU3763401A (en)	2001-09-17
WO2001066113A1 (fr)	2001-09-13
TR200401862T4 (tr)	2004-10-21
CA2402341A1 (fr)	2001-09-13
GB0005700D0 (en)	2000-05-03
ES2220727T3 (es)	2004-12-16
HK1053262A1 (en)	2003-10-17
NZ521228A (en)	2004-04-30
ATE267013T1 (de)	2004-06-15
PT1267869E (pt)	2004-10-29
DE60103384D1 (de)	2004-06-24
DK1267869T3 (da)	2004-09-20
US20030195139A1 (en)	2003-10-16

Publication	Publication Date	Title
GB0005700D0 (en)	2000-05-03	Therapy
DE60205776D1 (en)	2005-09-29	Indolinon-derivative als protein-kinasehemmer
ES2194960T3 (es)	2003-12-01	N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
MY121136A (en)	2005-12-30	Novel heterocyclic sulfonamides.
DK0901374T3 (da)	2004-04-05	Tetrahydropteridiner og pyridylpiperaziner til behandling af neurologiske forstyrrelser
MXPA03007140A (es)	2004-05-24	Derivados de carbolina.
DE60022692D1 (de)	2005-10-20	(S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
NZ544591A (en)	2009-07-31	Pyrrolodihydroisoquinolines as PDE10 inhibitors
MXPA03011197A (es)	2004-02-26	Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
MXPA06001008A (es)	2006-04-11	Derivados de 3-amino croman y 2-amino tetralina.
EP0986382A4 (fr)	2001-04-11	Inhibiteurs de raf kinase
EA200300717A1 (ru)	2003-12-25	Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
MXPA04002137A (es)	2004-06-29	Inhibidores de glicogen sintasa quinasa-3 (gsk-3) para el tratamiento del glaucoma.
EP2319527A3 (fr)	2011-10-12	BAFF, ses inhibiteurs et leur utilisation pour moduler la réponse immunitaire des cellules B et des immunoglobulines
ATE296809T1 (de)	2005-06-15	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ATE402149T1 (de)	2008-08-15	Heterozyklische substituierte amide, deren herstellung und anwendung
ATE305787T1 (de)	2005-10-15	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
AU2002358390A1 (en)	2003-06-30	Novel compounds
MXPA03007142A (es)	2004-05-24	Derivados de carbolina.
MXPA03010586A (es)	2004-04-02	N-[(1s)-1,2,3,4-tertrahidro-1-naftalenil benzamidas trisubtituidas, las cuales inhiben receptores que contienen p2x2/3.
ATE281439T1 (de)	2004-11-15	3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
SI1377574T1 (fr)	2005-08-31
YU22802A (sh)	2005-06-10	Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina
AU2002322396A1 (en)	2003-02-17	1-glycinyl-4 (methylpiperidin-4-yl) piperazines and -piperridines as factor xa antagonists
MXPA03006847A (es)	2003-11-13	Compuestos quimicos.